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TObjective: In a prospective phase II Food and Drug Administration trial, robotic
mitral valve repairs were performed in 112 patients at 10 centers by using the da
Vinci surgical system. The safety of performing valve repairs with computerized
telemanipulation was studied.
Methods: After institutional review board approval, informed consent was obtained.
Patients had moderate to severe mitral regurgitation. Operative technique included
peripheral cardiopulmonary bypass, a 4- to 5-cm right minithoracotomy, a trans-
thoracic aortic crossclamp, and antegrade cardioplegia. The successful study end
point was grade 0 or 1 mitral regurgitation by transthoracic echocardiography at 1
month after surgery.
Results: Valve repairs included quadrangular resections, sliding plasties, edge-to-
edge approximations, and both chordal transfers and replacements. The average age
was 56.4 0.09 years (mean SEM). There were 77 (68.8%) men and 35 (31.2%)
women. Valve pathology was myxomatous degeneration in 105 (91.1%), and 103
(92.0%) had type II leaflet prolapse. Leaflet repair times averaged 36.7  0.2
minutes, with annuloplasty times of 39.6  0.1 minutes. Total robot, aortic cross-
clamp, and cardiopulmonary bypass times were 77.9  0.3 minutes, 2.1  0.1
hours, and 2.8  0.1 hours, respectively. On 1-month transthoracic echocardiogra-
phy, 9 (8.0%) had grade 2 mitral regurgitation, and 6 (5.4%) of these had reopera-
tions (5 replacements and 1 repair). There were no deaths, strokes, or device-related
complications.
Conclusions: Multiple surgical teams performed robotic mitral valve repairs safely
early in development of this procedure, with a reoperation rate of 5.4%. Advance-
ments in robotic design and adjunctive technologies may help in the evolution of
this minimally invasive technique by decreasing operative times.
Traditionally, cardiac surgery has been performed through a median sternot-omy providing surgeons with generous operative exposure. Since 1995,improvements in perfusion technology and instrumentation have stimulated
cardiac surgeons to investigate the efficacy of minimally invasive cardiac proce-
dures. In large series of patients, Cohn and colleagues,1 Cosgrove and colleagues,2
and Navia and Cosgrove3 first reported improved outcomes and economic benefits
with minimal-access mitral valve (MV) and aortic valve surgery. Subsequently,
further developments in intracardiac visualization, instrumentation, and cannulation
methods hastened the development and expansion of minimally invasive cardiac
surgery.4,5 Because of these improvements, valve surgery performed through small
incisions is now standard practice for many surgeons.
Telemanipulation of tissues has become possible through recent advances in surgical
robotic systems, which provide a combination of 3-dimensional vision and microinstru-
mentation providing a full range of motion in tiny spaces, no tremor, and motion scaling.
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CSPIn 1998, Carpentier and Mohr independently performed the
first MV repairs by using an early prototype of the da Vinci
surgical system (Intuitive Surgical, Inc, Sunnyvale, Calif).6,7
Mohr and colleagues8 then reported the first operative series of
robotic MV procedures. Mehmnesh and colleagues9 have per-
formed the only closed-chest endoscopic MV repair to date.
Using the Zeus system, Grossi and colleagues10 performed a
posterior leaflet repair in 2000. A month later, with the da
Vinci system, Chitwood and colleagues11 performed a poste-
rior leaflet resection with reconstruction and implanted an
annuloplasty band.
TABLE 1. Institutions and investigators
Site
East Carolina University
Greenville, NC
Advocate Christ Hospital
Oak Lawn, Ill
Columbia Presbyterian Hospital
New York, NY
University of Southern California
Los Angeles, Calif
St Vincent’s Hospital
Portland, Ore
Carillon Roanoke Memorial Hospital
Roanoke, Va
INNOVA Fairfax Hospital
Fairfax, Va
Ohio State University
Columbus, Ohio
Brigham & Women’s Hospital
Boston, Mass
Baylor Healthcare System
Dallas, Tex
CS, Console surgeon; PSS, patient side surgeon.
TABLE 2. Robotic mitral surgery exclusion criteria
18 or 80 y of age
Previous right thoracotomy
Renal failure
Liver dysfunction
Bleeding disorders
Pulmonary hypertension (pulmonary artery systolic pressure
 60 mm Hg)
Concomitant MV stenosis
Anterior MV leaflet disease
Significant aortic or tricuspid valve disease
Coronary artery disease requiring surgery
Recent myocardial ischemia (30 d)
Recent stroke (30 d)
Severely calcified mitral valve annulus
2Body mass index 35 kg/m
1396 The Journal of Thoracic and Cardiovascular Surgery ● JunA phase I clinical trial (G000023) approved by the Food
and Drug Administration (FDA) was begun at East Carolina
University (ECU) to evaluate safety and efficacy in robot-
assisted MV repair surgery. In this initial series, patients were
between 18 and 80 years of age and had isolated grade 3/4
mitral regurgitation. All 10 patients had successful MV repairs,
with no deaths or complications.12 The FDA extended this trial
to 20 patients to provide training observation at ECU in prep-
aration for the forthcoming phase II trial. In October 2000, an
FDA-approved multicenter phase II trial (G000295) was initi-
ated to evaluate the system in a variety of institutional envi-
ronments. This report describes results from this 10-center
multicenter phase II clinical trial evaluating the da Vinci sur-
gical system in 112 MV repair patients.
Patients and Methods
Patients were enrolled by using FDA-approved selection criteria
after full institutional review board (IRB) approval at the respec-
tive institutions (Table 1). Each patient signed both IRB- and
FDA-approved consent forms after informed consent was ob-
tained. Between February 2001 and July 2002, 112 patients were
enrolled. Patients between 18 and 80 years of age with echocar-
diographically confirmed moderate (grade 3) to severe (grade 4)
regurgitation requiring a repair were screened for participation. All
patients underwent a history and physical examination followed by
a chest radiograph and transthoracic echocardiogram (TTE). Quan-
titation of valve regurgitation was obtained by Doppler color flow
imaging, spectral Doppler, and imaging for flow acceleration, as
well as measurement of proximal isovelocity surface area. The
Investigators No.
S: W. Randolph Chitwood Jr
SS: L. Wiley Nifong
22
S: Pat Pappas
SS: Anthony Tatooles
20
S: Craig Smith
SS: Michael Argenziano
15
S: Vaughn Starnes
SS: Daniel Schwarz
13
S: Jeffrey Swanson
SS: Michael Savitt
11
S: Joseph Baker
SS: Paul Frantz
9
S: Paul Massimiano
SS: Edward Lefrak
9
S: Robert Michler
SS: David Brown
7
S: Lawrence Cohn
SS: Lishan Aklog
4
S: Robert Hebeler
SS: Richard Wood
3C
P
C
P
C
P
C
P
C
P
C
P
C
P
C
P
C
P
C
Pseverity of the regurgitant jet was assessed by parameters includ-
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Ping the superior extent of the jet reaching the left atrial roof,
penetration into 1 or both upper pulmonary veins, and penetration
into the left atrial appendage. Subject exclusion criteria are out-
lined in Table 2. Each surgical team was trained at the Surgical
Robotic Training Center at ECU by using a curriculum-based
program that included case observation, didactic sessions, and both
inanimate and cadaver models.13
All patients were intubated for single-lung ventilation. Both
a pulmonary artery catheter and a 17F venous drainage cannula
were placed percutaneously into the right internal jugular vein.
A transesophageal echocardiographic (TEE) probe was posi-
tioned after intubation. External defibrillator patches were
placed to subtend the maximum cardiac mass. Each patient was
positioned with the right chest elevated approximately 40° and
TABLE 3. MV pathology and etiology
Variable
Total
(n  112)
BAY
(n  3)
BWH
(n  4)
CAR
(n  8) (n
Etiology
Myxomatous 105 (91.1) 3 (100) 4 (100) 8 (100) 12
Other 7 (6.3) 0 0 0 3
Leaflet dysfunction*
Type I 5 (4.5) 0 0 0 1
Type II 103 (92.0) 3 (100) 4 (100) 8 (100) 14
Type III 1 (1.7) 0 0 0 0
Other 3 (2.7) 0 0 0 0
Valve pathology
Leaflet prolapse 105 (93.8) 3 (100) 4 (100) 8 (100) 14
Chordal rupture 63 (56.3) 1 (33.3) 3 (75.0) 1 (12.5) 6
Isolated annular
dilatation
6 (5.4) 0 0 0 1
Leaflet perforation 1 (0.9) 0 0 0 1
BAY, Baylor Healthcare System; BWH, Brigham & Women’s Hospital; CAR,
Advocate Christ Hospital; ECU, East Carolina University; FRX, INNOVA F
University of Southern California. Data are n (%). *Leaflet dysfunction as 
TABLE 4. Mitral valve repair techniques
Variable
Total
(n  112)
BAY
(n  3)
BWH
(n  4)
CAR
(n  8) (
Isolated annuloplasty
(P .06)
11 (9.8) 1 (33.3) 0 0
Quadrangular
resection
(P  .0001)
81 (72.3) 2 (66.7) 4 (100) 8 (100) 1
Sliding plasty
(P  .0002)
5 (4.5) 2 (66.7) 0 0
Chordal repair,
replacement, or
shortening
(P  .0001)
15 (13.4) 0 0 0
BAY, Baylor Healthcare System; BWH, Brigham & Women’s Hospital; CAR,
Advocate Christ Hospital; ECU, East Carolina University; FRX, INNOVA F
University of Southern California. Data are n (%).with the right arm suspended on a padded armrest above the
The Journal of Thoracicforehead. Femoral arterial and venous cannulation was per-
formed through a 2-cm transverse right groin incision by using
the Seldinger guidewire method and TEE guidance. Bicaval
venous drainage was instituted through the jugular and femoral/
inferior vena cava cannulas. A 5- to 6-cm submammary right
minithoracotomy was made, and the fourth intercostal space
(ICS) was entered after right lung deflation. The details of
intrathoracic preparation have been described in other publica-
tions.14 Cardioplegia administration routes varied depending on
institutional choice. Aortic occlusion was performed by using
either a transthoracic crossclamp or an endoaortic balloon.
Carbon dioxide was insufflated continuously into the operative
field for air displacement. An interatrial groove left atriotomy
was performed, and each MV was exposed by using a trans-
)
CRH
(n  20)
ECU
(n  22)
FRX
(n  9)
OSU
(n  7)
STV
(n  11)
USC
(n  13)
) 20 (100) 19 (86.4) 9 (100) 6 (85.7) 11 (100) 13 (100)
) 0 3 (13.6) 0 1 (14.3) 0 0
0 1 (4.6) 0 2 (28.6) 1 (9.1) 0
) 20 (100) 19 (86.4) 9 (100) 5 (71.4) 10 (90.9) 11 (84.6)
0 1 (4.6) 0 0 0 0
0 1 (4.6) 0 0 0 2 (15.4)
) 20 (100) 19 (86.4) 9 (100) 5 (71.4) 10 (90.9) 13 (100)
) 12 (60.0) 12 (54.6) 7 (77.8) 3 (42.9) 9 (81.8) 9 (69.2)
0 2 (9.1) 0 2 (28.6) 1 (9.1) 0
0 0 0 0 0 0
on Roanoke Memorial Hospital; COL, Columbia Presbyterian Hospital; CRH,
Hospital; OSU, Ohio State University; STV, St Vincent’s Hospital; USC,
ed by the Carpentier classification.15
15)
CRH
(n  20)
ECU
(n  22)
FRX
(n  9)
OSU
(n  7)
STV
(n  11)
USC
(n  13)
) 0 3 (13.6) 0 3 (42.9) 2 (18.2) 1 (7.7)
.7) 20 (100) 14 (63.6) 9 (100) 4 (57.1) 7 (63.6) 0
) 0 2 (9.1) 0 0 0 0
0 2 (9.1) 1 (9.1) 0 0 12 (92.3)
on Roanoke Memorial Hospital; COL, Columbia Presbyterian Hospital; CRH,
Hospital; OSU, Ohio State University; STV, St Vincent’s Hospital; USC,COL
 15
(80.0
(20.0
(6.6)
(93.3
(93.3
(40.0
(6.7)
(6.7)
Carill
airfaxCOL
n 
1 (6.7
3 (86
1 (6.7
0
Carill
airfaxthoracic intra-atrial retractor (CardioVations, Somerville, NJ).
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CSPda Vinci instrument arms (7 mm) were inserted through two
10-mm trocar incisions. The right instrument arm generally was
positioned 4 to 6 cm lateral to the chest incision in either the fourth
or fifth ICS. The left instrument arm was positioned medial and
cephalad to the right arm in the second or third ICS. Arm trocar
sites were maintained 6 cm apart at chest entry. Care was taken to
establish optimal arm-vector alignment with the valve plane to
ensure full, unrestricted instrument excursion. A specialized 30°
stereoscopic endoscope was placed through the medial portion of
the minithoracotomy. A patient-side surgeon facilitated instrument
changes and needle/suture passing and retrieval. All valve repair
and annuloplasty sutures were placed with the da Vinci robot. All
left atriotomies were closed either under direct vision or with
videoscopic assistance. After crossclamp release, meticulous in-
tracardiac deairing and weaning from cardiopulmonary bypass
(CPB) was performed, and pacing wires and chest tubes were
inserted. In each patient, a postrepair TEE was performed for
analysis by the outside echocardiographic core laboratory.
Clinical information for enrolled patients was collected and
verified by trained study monitors. All data were abstracted onto
FDA case report forms and entered into a database. Case report
forms were completed for the following points: (1) before surgery,
(2) during surgery, (3) after surgery (including the intensive care
TABLE 5. Operative characteristics, including times
Variable
Total
(n  112)
BAY
(n  3)
BWH
(n  4)
CAR
(n  8)
Operation time (P  .0001) (min)
Mean 266.4 309.0 334.3 243.8
SD 73.0 55.7 43.4 23.6
Range 150-463 263-371 298-392 218-286
CPB time (P  .0001) (min)
Mean 168.8 164.3 222.3 193.3
SD 47.3 8.7 54.0 10.5
Range 82-316 157-174 175-300 173-205
Aortic crossclamp time (P  .0001) (min)
Mean 124.1 131.3 173.3 135.6
SD 34.0 11.0 36.9 14.1
Range 60-227 124-144 148-227 112-156
da Vinci time (P  .0001) (min)
Mean 77.9 44.7 114.5 84.1
SD 30.3 15.0 18.7 13.2
Range 21-171 28-57 97-141 60-97
Annuloplasty time (P  .0001) (min)
Mean 39.6 44.0 52.5 38.9
SD 13.6 6.6 3.5 4.1
Range 17-79 37-50 49-56 33-45
Leaflet repair time (P  .0001) (min)
n 101 2 4 8
Mean 36.7 36.0 45.8 39.6
SD 20.4 1.4 10.3 12.2
Range 5-115 35-37 35-38 22-60
BAY, Baylor Healthcare System; BWH, Brigham & Women’s Hospital; CAR,
Advocate Christ Hospital; ECU, East Carolina University; FRX, INNOVA F
University of Southern California; CPB, cardiopulmonary bypass.unit), (4) at discharge, and (5) 1 month after surgery. All adverse
1398 The Journal of Thoracic and Cardiovascular Surgery ● Junevents were recorded and reported immediately. All echocardio-
grams were reviewed by an independent core laboratory (Hoag
Memorial Hospital, Newport Beach, Calif). These included pre-
operative TTE, intraoperative TEE before and after each MV
repair, and a TTE 1 month after surgery. Intraoperative TEE was
performed before institution of CPB and after the valve repair after
weaning from bypass. The core laboratory was blinded to echo-
cardiogram findings at each site, and individual sites were blinded
to the core laboratory findings. Significant discrepancies were
resolved by reanalysis of the echocardiography tapes in question.
The core laboratory assessment was used in the final analysis.
All final data analyses were conducted with SAS (SAS Insti-
tute, Cary, NC). All continuous variables were analyzed with
nonparametric tests, the Wilcoxon ranked sum test for 2-group
comparisons, and Kruskal-Wallis analysis of variance for multi-
group comparisons. Categorical data were analyzed with 2 tests.
Data are shown as mean  SD and range.
Results
Between February 2001 and July 2002, 112 patients with
grade 3/4 mitral regurgitation underwent a robotic MV
repair with the da Vinci surgical system. Operation at each
OL
15)
CRH
(n  20)
ECU
(n  22)
FRX
(n  9)
OSU
(n  7)
STV
(n  11)
USC
(n  13)
6.0 199.7 265.1 295.7 269.6 255.5 203.7
8.3 35.1 47.7 53.0 62.0 28.5 46.8
-463 154-287 198-372 247-414 201-382 196-292 150-306
7.3 126.9 162.7 201.7 164.4 164.5 128.9
2.6 24.3 28.5 42.3 35.7 25.0 27.5
-316 95-175 113-216 166-300 117-223 113-188 82-183
5.3 89.8 124.6 152.2 134.9 132.5 95.5
0.9 22.3 20.3 35.8 39.2 26.6 18.9
213 60-143 87-163 117-226 82-196 83-177 67-136
9.9 65.6 86.8 79.2 66.9 72.6 46.5
4.1 24.2 16.1 30.0 31.3 27.9 14.1
171 42-128 52-128 60-152 21-115 25-113 29-75
0.5 28.1 42.4 46.9 47.0 37.5 28.2
3.5 6.7 13.5 11.0 14.7 13.7 9.1
-76 19-40 27-79 38-74 25-70 17-56 20-54
4 20 19 9 4 9 12
8.1 20.7 38.9 48.3 61.3 51.8 13.3
5.7 11.9 14.7 11.1 17.5 18.5 8.6
115 9-53 19-67 33-70 49-87 29-84 5-36
on Roanoke Memorial Hospital; COL, Columbia Presbyterian Hospital; CRH,
Hospital; OSU, Ohio State University; STV, St Vincent’s Hospital; USC,C
(n 
38
4
293
22
5
140
14
3
96-
10
3
61-
5
1
34
1
4
2
20-
Carill
airfaxsite was performed by the same console surgeon and up to
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P2 patient-side surgeons. At study initiation, 324 patients met
the initial screening criteria; however, 212 (65.4%) patients
were ineligible because of issues related to the inclusion/
exclusion criteria (Table 2). Ineligibility was due to con-
comitant coronary artery disease (n  61; 30.8%), tricuspid
valve disease (n  49; 24.7%), aortic insufficiency/stenosis
(n  15; 7.5%), and anterior MV leaflet disease requiring
repair (n 15; 7.5%). One hundred twelve patients (34.6%)
were enrolled in the study.
The average age of all patients was 56.4  10.2 years,
with a range of 37 to 81 years. The average body mass index
TABLE 6. Postoperative characteristics, including times
Variable
Total
(n  112)
BAY
(n  3)
BWH
(n  4)
CAR
(n  9)
COL
(n  4)
Ventilation time (h)
Mean 9.1 6.3 15.3 5.5 19.5
SD 12.6 1.2 17.9 3.0 27.1
Range 0-112 5-7 5-42 2-10 2-112
ICU time (h)
Mean 36.6 31.3 53.0 26.5 48.2
SD 24.7 12.1 45.1 9.6 41.8
Range 6-140 22-45 22-119 21-50 17-140
Length of stay (d)
Mean 4.7 6.3 7.0 4.4 6.3
SD 3.0 0.6 6.0 1.7 3.5
Range 1-18 6-7 4-16 3-7 3-18
BAY, Baylor Healthcare System; BWH, Brigham & Women’s Hospital; CAR,
Advocate Christ Hospital; ECU, East Carolina University; FRX, INNOVA F
University of Southern California; ICU, intensive care unit.
TABLE 7. Intraoperative TEE by the core echocardiograph
Variable Total BAY BWH CAR COL
Prerepair regurgitation grade
Number 107 3 3 8 14
None — — — — —
1 — — — — —
2 3 (2.8) 0 0 0 1 (7.1
3 68 (63.6) 3 (100) 2 (66.7) 6 (75) 6 (42.
4 36 (33.6) 0 1 (33.3) 2 (25) 7 (50
Not reported 5
Postrepair regurgitation grade
Number 108 3 4 7 14
None 78 (72.2) 3 (100) 1 (25.0) 5 (71.4) 9 (64.
1 29 (26.9) 0 3 (75.0) 1 (14.3) 5 (35.
2 1 (0.9) 0 0 1 (14.3) 0
3 — — — — —
4 — — — — —
Not reported 4
BAY, Baylor Healthcare System; BWH, Brigham & Women’s Hospital; CAR,
Advocate Christ Hospital; ECU, East Carolina University; FRX, INNOVA F
University of Southern California. Data are n (%).was 26.6  4.0 kg/m2 (18.5 to 40.9 kg/m2). Of the 112
The Journal of Thoracicpatients, 77 were male (68.8%), and 102 (91.1%) were
white. The most prevalent comorbid conditions were a
family history of coronary artery disease (n  59; 52.7%),
smoking (n  39; 34.8%), cardiac arrhythmias (n  33;
29.5%), hypertension (n  39; 34.8%), congestive heart
failure (n 22; 19.6%), and cardiomegaly (n 20; 17.9%).
There was a significantly lower prevalence of peripheral
vascular disease (n 5; 4.5%), infectious endocarditis (n
6; 5.6%), diabetes (n  3; 2.6%), and rheumatic fever (n 
6; 5.6%). No statistically significant differences in demo-
graphic characteristics were found among the patients
CRH
 20)
ECU
(n  22)
FRX
(n  9)
OSU
(n  7)
STV
(n  11)
USC
(n  13)
0.8 10.6 6.7 12.3 5.5 11.8
1.7 5.3 4.4 5.0 5.0 11.2
0-5 4-31 3-17 7-19 2-20 3-43
37.2 25.8 30.7 32.3 30.2 55.0
20.3 13.0 13.7 13.5 12.2 27.3
-81 8-70 19-56 20-52 19-51 16-98
2.8 4.3 3.9 4.9 6.1 5.1
3.4 1.6 1.0 1.1 4.6 2.0
-16 3-9 2-5 4-7 3-18 3-9
on Roanoke Memorial Hospital; COL, Columbia Presbyterian Hospital; CRH,
Hospital; OSU, Ohio State University; STV, St Vincent’s Hospital; USC,
oratory
CRH ECU FRX OSU STV USC
19 21 8 7 11 13
— — — — — —
— — — — — —
0 1 (4.8) 0 1 (14.3) 0 0
15 (78.9) 15 (71.4) 2 (25) 4 (57.1) 8 (72.7) 7 (53.8)
4 (21.1) 5 (23.8) 6 (75) 2 (28.6) 3 (27.3) 6 (46.1)
20 21 8 7 11 13
12 (60.0) 15 (71.4) 7 (87.5) 6 (85.7) 9 (81.8) 11 (84.6)
8 (40.0) 6 (28.6) 1 (12.5) 1 (14.3) 2 (18.2) 2 (15.4)
0 0 0 0 0 0
— — — — — —
— — — — — —
on Roanoke Memorial Hospital; COL, Columbia Presbyterian Hospital; CRH,
Hospital; OSU, Ohio State University; STV, St Vincent’s Hospital; USC,(n
6
1
Carill
airfaxy lab
)
9)
)
3)
7)
Carill
airfaxenrolled.
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CSPTable 3 shows both the pathologies and etiologies of
regurgitation in these patients. As expected, most patients
had myxomatous MV degeneration (n  105; 91.1%), re-
sulting primarily in Carpentier classification type II leaflet
prolapse (n  103; 92.0%).15 Although prolapse was ob-
served most often, approximately half of the patients had
other reasons for valvular insufficiency, including chordal
rupture (n 65; 56.3%) and isolated annular dilatation (n
6; 5.4%). Of the 112 patients, 101 (90.2%) had a valvulo-
plasty, and all 112 (100%) had a posterior band annulo-
plasty. As seen in Table 4, the most common valvuloplasty
performed was a leaflet resection (n  81; 72.3%). In
addition, 15 (13.4%) patients had a chordal repair, pros-
thetic replacement, or transfer.
Intraoperative procedural times are shown in Table 5. Of
the 101 patients undergoing leaflet repairs, the average time
required for excision and reconstruction was 36.7  20.4
minutes (range, 5-115 minutes). The 112 annuloplasty band
implantations averaged 39.6  13.6 minutes (range, 17-79
minutes) to complete. Mean aortic crossclamp and CPB
times were 124.1  34.0 minutes (range, 60-227 minutes)
and 168.8  47.3 minutes (range, 82-316 minutes), respec-
tively. Finally, the average time for da Vinci system use was
77.9  30.3 minutes (range, 21-171 minutes). Of the 112
patients, 25 (22.3%) required intraoperative or postopera-
tive blood replacement products. The 19 patients transfused
with packed red blood cells (16.9%) required an average of
2.5  0.9 units (range, 1 to 4 units), and 5 patients (4.5%)
received 2.6  1.1 units (range, 1-4 units) of fresh frozen
plasma. Six (5.4%) patients were transfused with 4.0  2.6
units (range, 1-8 units) of platelets. Intubation, intensive
care, and total hospitalization times are shown in Table 6.
The mean ventilation time for the group was 9.1  12.6
hours (range, 0-112 hours), with ICU stays averaging 36.6
 24.7 hours (range, 6-140 hours). The length of hospital
stay for all patients was 4.7  3.0 days (range, 1-18 days).
All patients had a preoperative TTE within 1 month of
trial enrollment. Of the 112 patients, 109 (97.3%) had either
grade 3 or 4 regurgitation. The mean preoperative left
ventricular ejection fraction was 64.1%  6.8% (range,
35%-75%). The Kruskal-Wallis test for analysis of variance
showed no significant differences in the severity of either
MV regurgitation or left ventricular ejection fraction across
institutions (P  .5 and P .22, respectively). The intraop-
erative TEE results before and after surgical repairs are
shown in Table 7. The prerepair TEE results were similar to
the results of the TTE studies. Of the 107 patients with a
prerepair intraoperative TEE, 104 (97.2%) had either grade
3 or 4 mitral regurgitation. Of the 107 patients with TEE
results, 79 (73.8%) had isolated posterior leaflet disease,
whereas 26 (24.3%) had some involvement of both the
posterior and anterior leaflets. The postrepair intraoperative
TEE showed all but 1 patient to have either grade 1 or no
1400 The Journal of Thoracic and Cardiovascular Surgery ● JunMV regurgitation. Immediate postoperative TEE results
confirmed reversion in 99.1% of patients from grade 3/4
regurgitation to either grade 1 or no leak. No significant
differences in either preoperative or postoperative regurgi-
tation grades were found across sites (P .32 and P .05,
respectively).
Of the 112 patients enrolled in the study, 1-month post-
operative follow-up TTE showed that 103 (92.0%) had
either no or grade 1 regurgitation. Seven (6.3%) had grade
2 regurgitation, and 2 (1.8%) had either grade 3 or 4 leaks.
Of these 9 patients, 3 with grade 2 regurgitation are being
followed up and have not required reoperation because they
have no clinical symptoms. The first of these 3 patients had
a type II posterior leaflet prolapse with chordal ruptures and
elongations, combined with annular dilatation. A posterior
leaflet resection was performed along with a band annulo-
plasty. The postrepair TEE showed no regurgitation. The
second patient had a restricted posterior mitral leaflet with
thickened edges. A posterior annuloplasty was performed
with no leaflet resection. The immediate postrepair TEE
showed grade 1 regurgitation. The third patient had Barlow
disease with prolapse of the anterior A2 and posterior P2
leaflet segments. An edge-to-edge leaflet repair was per-
formed, followed by a posterior annuloplasty. The postre-
pair TEE showed grade 1 regurgitation.
Of the 9 patients with more than grade 1 insufficiency at
the follow-up TTE, 6 (5.3%) had either grade 2 or 3 regur-
gitation and required reoperations. Four of the 6 patients had
a type II leaflet prolapse repaired with a leaflet resection and
annuloplasty band. Three of these 4 had grade 1 regurgita-
tion by TEE after repair, and the fourth had systolic anterior
motion. All 4 patients had MV replacements with a me-
chanical valve. At reoperation, 1 had a dehiscence of the
repair, but the other 3 repairs were intact but with new
leakage. One of the 6 patients who required reoperation had
a type II prolapse with a chordal rupture. The valve was
repaired initially with a chordal replacement and annulo-
plasty band insertion. The postrepair TEE for this patient
showed no regurgitation. However, a follow-up TTE
showed a grade 2 leak at the posterior annulus. Four months
after the first operation, the patient presented with a partial
band dehiscence that caused hemolysis necessitating valve
replacement. The remaining patient initially had grade 3
mitral regurgitation secondary to type 3 posterior leaflet
restriction. The robotic repair consisted of a band annulo-
plasty, and the initial postrepair TEE showed only trace
mitral regurgitation. However, the follow-up TTE showed
grade 2 regurgitation with a central jet. Because the patient
was symptomatic, the valve was replaced with a
bioprosthesis.
There were no operative or midterm deaths; however,
there were 11 major adverse events. The 6 that necessitated
reoperations were discussed previously. Other complica-
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Ptions included bleeding (re-exploration, n 3), a pericardial
effusion (drainage, n 1), and a myocardial infarction (n
1). There were no intraoperative conversions to alternative
surgical techniques (eg, sternotomy or thoracotomy enlarge-
ment), and there were no da Vinci system–related adverse
events. All procedures that were started with the da Vinci
system were completed with robotic assistance.
Generalized estimating equations were used to analyze
the learning curves associated with da Vinci system MV
repairs. This model considers the correlation structure in-
volved with repeated measures for a given surgeon/site
participating in the trial. In patients requiring resections,
CPB times decreased by 4.3 minutes per progressive case
(Figure 1, A). In this same group, the mean aortic cross-
clamp time decreased by 3.7 minutes per case, and total
operative times decreased by 4.4 minutes per case (Figure 1,
B and C).
Discussion
Continually improving MV repair methods have rendered
outstanding results, but sternotomy still remains the ap-
proach of choice for most surgeons. Carpentier and others
have shown enviable repair results that have persisted for 15
to 20 years, thus establishing this approach as the “gold
standard.”16 Recently, minimally invasive techniques have
been developed for valve operations. Partial sternotomies,
parasternal incisions, and minithoracotomies were first used
to reduce surgical trauma and to minimize hospitalization
and transfusions. Beginning in 1995, Cosgrove,2 Cohn,1
Grossi,17 and their associates led this effort, and their results
paralleled those of sternotomy-based repairs.1,2,17 To date,
surgeons at the Cleveland Clinic have performed well over
2500 minimally invasive valve operations by combining
direct vision with an upper hemisternotomy and modified
perfusion techniques. Their minimal-access patients had
less than a 1.0% mortality, reduced transfusions (10%),
and earlier hospital discharge compared with those who had
sternotomy.18 Complex operations were performed by these
surgeons, as evidenced by their first 607 minimally invasive
aortic valve operations, in which 25% were repairs and 26%
were homograft replacements. Cohn has performed more
than 1000 minimally invasive aortic and MV operations,
with similar excellent results.2 His reoperative rate for MV
repair was 3.0%, compared with 6.9% for 893 patients in the
2001 STS database. Similarly, the New York University
group reported 375 MV repairs with minithoracotomy, en-
doaortic balloon occlusion, and direct vision.17 Again, low
operative mortality (1.1%) and good results were shown for
complex repairs. Of these patients, 89% had only trace or no
residual regurgitation by TEE after the repair.
Despite these and other successful minimally invasive
valve operations, most surgeons have not embraced endo-
scopic methods for MV surgery. Onnasch and associates19
The Journal of Thoracicand Chitwood and Nifong18 independently showed that
endoscopic MV surgery can be performed safely and with
“gold standard” results, but in most instances their opera-
tions were video assisted rather than totally endoscopic.5 In
contradistinction, Schroeyers and associates20 have shown
that excellent MV repairs can be performed endoscopically
by using 2-dimensional visualization and endoaortic occlu-
sion. Few surgeons to date have adopted these methods
because of the difficult transition from a wide-access, direct-
vision cardiac operation to a completely endoscopic one that
requires a combination of new technologies.
By limiting direct access to the valve, visualization be-
comes impaired, instrument manipulation is encumbered,
and surgeon confidence in the safety and quality of the
Figure 1. Mean cardiopulmonary bypass (CPB) time (A), cross-
clamp time (B), and operating time (C) in MV repair cases requir-
ing leaflet resection.operation may wane. Surgical telemanipulation seems the
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incisions and in restricted spaces. Robotic technology can
provide many potential benefits to cardiac surgeons. Cuta-
neous incisions can be smaller because of improved optics
and instrumentation. Moreover, wristlike articulations trans-
fer the dexterous actions of instrument tips to the plane of
the annulus and the papillary muscle level. With the addi-
tion of tremor filtration, there is improved precision in tight
intracardiac spaces. Moreover, ambidexterity can become a
reality for all surgeons. With these devices, leaflet resec-
tions, chordal transfers, and sliding plasties can be com-
bined with a band or ring annuloplasty to perform complete
repairs.12
The results reported herein represent an FDA-approved
robotic MV surgery multicenter trial in which experienced
MV repair surgeons from 10 centers enlisted patients into a
standardized IRB- and FDA-approved protocol. In each
patient, the major portion of each operation was performed
robotically from a console removed from the operating
table. The robotic system performed safely and efficiently,
with no operative deaths or conversions due to a system
malfunction. Moreover, there were no incision conversions
either to a larger thoracotomy or to a median sternotomy.
These patients benefited from minimal musculoskeletal
trauma, a low transfusion rate, and early discharge. Al-
though there were no operative mortalities and few compli-
cations, 6 patients required reoperations, of which 5 had
valve replacements and 1 had a second band annuloplasty.
Although these patients had either no or less than grade 1
regurgitation on the postrepair TEE, they presented within 4
months with grade 3/4 regurgitation and symptoms. Repair
failures were spread over 4 institutions, all of which had
enrolled at least 10 patients in the study. Compared with the
STS database, patients in the multicenter robotic trial had
significantly lower mortality, fewer neurologic complica-
tions, and shorter lengths of hospital stay. Moreover, robotic
MV patients tended to have fewer reoperations and overall
complications than those in the STS cohort. Transfusion
requirements were low (22.3%) and paralleled those of
other minimally invasive valve operative series.21 Despite
these benefits, crossclamp and perfusion times were signif-
icantly longer in the robot trial patients. The most significant
complication, other than recurrent leakage, was a myocar-
dial infarction in a patient secondary to right coronary artery
air embolism.
In previous studies, residual regurgitation has been re-
ported as an independent risk factor for reoperation.15 Lim
and colleagues22 showed that approximately 59% of pa-
tients have clinically insignificant regurgitation after a re-
pair. As seen in this series, most repair failures occur, are
detected, and are addressed in the early postoperative pe-
riod. Other authors have shown a mean regurgitant grade of
0.7 after a minimally invasive MV repair.21,23 In the 112
1402 The Journal of Thoracic and Cardiovascular Surgery ● Junpatients described herein, the mean grade of mitral regur-
gitation was 3.7 before surgery and 0.5 after surgery on the
TTEs analyzed by the core laboratory.
Operative times were longer in this series compared with
conventional sternotomy procedures. However, the learning
curves demonstrate a progressive decline in crossclamp,
CPB, and resection times, as well as overall operative times,
in patients having repairs with or without leaflet resections.
One can expect that operations performed early in the series
would require longer times than those performed after both
the surgeon and team have become familiar with the pro-
cedure. This same occurrence has been found in video-
assisted MV repair series.24 As surgical teams become even
more facile in using these devices, perioperative times can
be expected to continue to decrease. Moreover, evolving
adjunctive technology, such as annuloplasty band clips, may
speed these operations even more.
Study limitations were primarily related to the investiga-
tion of an optimal study population with few comorbidities
in the patients enrolled. FDA inclusion/exclusion criteria
resulted in the exclusion of any patients with conditions
such as coronary artery disease, mitral stenosis, bileaflet
disease, significant aortic or tricuspid valve pathology, mi-
tral annular calcification, morbid obesity, recent myocardial
infarction or stroke, and poor ventricular function.
In summary, this multicenter study has shown that MV
repairs can be performed safely in low-risk patients with
potential patient benefits by multiple surgeons and teams.
Despite the prearranged expertise of these surgeons, this
series does suggest a higher early reoperative rate with the
robotic methods than with other direct-vision, limited-
access MV repairs. However, these data compare favorably
to conventional repairs performed by multiple surgeons
through a sternotomy. With the evolution of robotic surgical
systems, surgeons and their patients can expect to gain the
benefits shown in this study.
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Discussion
Dr Friedrich W. Mohr (Leipzig, Germany). I would like to
congratulate the authors on a very successful prospective multi-
center phase II FDA trial performing total endoscopic MV repair
in 112 patients by using the Intuitive telemanipulation system. In
1998, Professor Carpentier and I independently performed the first
MV repairs by using this system. Optimal visualization, precise
cutting, and suturing seemed to be very advantageous as compared
with normal endoscopic instruments.
In our own series, we have completed 26 of 28 successful MV
repairs, including very complex repairs. We had to learn that the
current technology still is suboptimal, and it was very hard to
manage simple techniques such as the implantation of a complete
remodeling ring and time-consuming knot tying.
During the past 3 years, we favored video-assisted surgery for
routine use. However, we are working together with Intuitive on a
The Journal of Thoracicconcept for better teaching and training in endoscopic MV repair
by using 2 consoles to apply computer simulation.
This article demonstrates very nicely that this type of MV
surgery has been successfully introduced in the United States and
has been further developed, especially by Dr Chitwood’s group. I
want to congratulate all the centers and authors for this tremendous
work.
One has to understand that the results being presented reflect
the situation of a completely new operation, and one has to accept
that every surgeon has had to learn how to do it. There was no
mortality, and there were no major intraoperative complications or
neurologic deficits. The initial success rate of MV repair was very
high: 99.1%.
I would like to ask 3 questions. You were mentioning that every
team went through a special training for robotic MV surgery
before clinical application. Can you elaborate on this and describe
what was deemed to be necessary? Did all the centers have
experience in minimally invasive video-assisted MV surgery?
Ten centers contributed to the study. Patient enrollment varied
between 3 and 22 patients depicting different stages in the learning
curves. Furthermore, you could demonstrate a clear improvement
per given case concerning mean times of surgery, mean cross-
clamp times, and so on. How many patients should one operate on
to feel comfortable?
The failure rate of successful MV repair was 9 (8%) of 112
within 1 month; 6 patients needed reoperation. Even if this reop-
eration rate compares favorably to the STS database rates, it seems
high to me, because you were dealing with highly selected patients
with uncomplicated MV disease. Do you think this may be due to
the compromise of using a posterior band instead of a remodeling
ring in such patients or inadequate compression by the suture
technique?
Dr Nifong. Professor Mohr, thank you very much for your kind
words and also legitimate criticisms. It is an honor to have our
article reviewed by a pioneer in the field of robotic and minimally
invasive cardiac surgery. Your team in Leipzig has contributed a
great deal to this field.
To answer your first question regarding training for robotic
mitral valve surgery, we have an intense 2-day program for
training surgical teams. This occurs after teams have completed
the “system” training, which is when they learn how to use the
system and perform troubleshooting for potential problems.
Valve training includes live case observation in the operating
room followed by didactic discussion and review of the case.
Issues related to peripheral cardiopulmonary bypass, aortic
occlusion, cardioplegia administration, and deairing are re-
viewed and discussed.
We then spend a day and a half in the robotic laboratory using
inanimate models, porcine hearts, and cadavers. We review each
step of the procedure, including patient positioning, incisions,
exposure, cannulation, retraction, and positioning of both the ro-
botic surgical cart and instruments. All centers involved in the
multicenter trial had experience in minimally invasive mitral valve
surgery. However, at this time we are training teams with less
minimally invasive or videoscopic experience, and they perform
very well.
To answer your second question, we have performed 81
robotic mitral valve procedures and recently reviewed all the
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to complete approximately 15 cases before times begin to
decrease.
To answer your third question, we are very sensitive to the
issue regarding the 6 patients who required reoperation. One
concerning issue is that none of those patients had more than
grade 1 mitral regurgitation by postrepair transesophageal echo-
cardiography, and these readings were by an off-site cardiolo-
gist blinded to the institution and procedure performed. At
follow-up, these patients had advanced to grade 2 or worse1404 The Journal of Thoracic and Cardiovascular Surgery ● JunAs you are aware, it is quite difficult to manage a more rigid
ring in the small space of the left atrium by using the robotic
system; however, it can be done, and we have recently performed
2 valve replacements. We are currently working on ideas related to
a new type of annuloplasty ring that may answer this problem and
allow one to perform a full remodeling annuloplasty, if needed.
We do not believe that the suturing technique is a problem. The
high magnification of vision systems allows the surgeon to see the
compression and tightness of the knots. Air knots are easily seen
and avoided.mitral regurgitation. Thank you again for reviewing our article.e 2005
